Related Experiment Video

Updated: Aug 10, 2026

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
19:44

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen

Published on: May 30, 2012

Mechanisms of resistance to TRAIL-induced apoptosis in cancer

Lidong Zhang1, Bingliang Fang

  • 1Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.

Cancer Gene Therapy
|November 20, 2004
PubMed

Insights

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) shows anticancer potential but faces resistance. Understanding TRAIL resistance mechanisms is key to improving cancer therapy effectiveness.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Death Research

Background:

  • The tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a promising anticancer agent.
  • However, significant numbers of cancer cells, particularly highly malignant tumors, exhibit resistance to TRAIL-induced apoptosis.
  • Acquired resistance can also develop in initially sensitive cancer cells after repeated TRAIL exposure.

Purpose of the Study:

  • To elucidate the molecular mechanisms underlying resistance to TRAIL-induced apoptosis in cancer cells.
  • To identify potential strategies for overcoming TRAIL resistance in cancer therapy.

Main Methods:

  • Analysis of signaling pathways involved in TRAIL-induced apoptosis.
  • Investigation of genetic and protein expression alterations contributing to resistance.
  • Examination of mitochondrial pathways and regulatory factors in TRAIL resistance.

Main Results:

  • TRAIL resistance can arise from defects in death receptors (DR4/DR5), adaptor proteins (FADD), or caspase-8.
  • Overexpression of cFLIP, Bcl-2, Bcl-X(L), or inhibitors of apoptosis proteins contributes to resistance.
  • Mitochondrial dysfunction, including reduced Smac/Diablo release, and aberrant MAPK/NF-κB signaling pathways are implicated in TRAIL resistance.

Conclusions:

  • TRAIL resistance is a multifaceted issue involving multiple points in apoptosis signaling pathways.
  • Targeting these resistance mechanisms, such as modulating cFLIP or mitochondrial pathways, could enhance TRAIL efficacy in cancer treatment.

More Related Videos

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel06:44

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

Flow Cytometric Detection of Newly-formed Breast Cancer Stem Cell-like Cells After Apoptosis Reversal11:21

Flow Cytometric Detection of Newly-formed Breast Cancer Stem Cell-like Cells After Apoptosis Reversal

Published on: January 26, 2019

Related Concept Videos

Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
The Extrinsic Apoptotic Pathway01:17

The Extrinsic Apoptotic Pathway

The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...